



Inventor Name Search.

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Thursday
Date: 2/15/2007

Time: 13:32:41

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

Sperry

David

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Thursday
Date: 2/15/2007

Time: 12:51:24

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

Gao

Ping

Search

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

 PALM INTRANET

Day : Thursday
Date: 2/15/2007

Time: 13:17:14

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name**First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Freeform Search

Database:	US Pre-Grant Publication Full-Text Database
	US Patents Full-Text Database
	US OCR Full-Text Database
	EPO Abstracts Database
	JPO Abstracts Database
	Derwent World Patents Index
	IBM Technical Disclosure Bulletins

Term:	L41 and (soft near8 "gelatin capsule")
--------------	----------------------------------------

Display:	20	Documents in Display Format:	CIT	Starting with Number	1
-----------------	----	-------------------------------------	-----	-----------------------------	---

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search Clear Interrupt

Search History

DATE: Thursday, February 15, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name result set</u>
side by side			
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L42</u>	L41 and (soft near8 "gelatin capsule")	66	<u>L42</u>
<u>L41</u>	L40 and (surfactant or "polysorbate 80")	278	<u>L41</u>
<u>L40</u>	L39 and (antioxidant or "anti-oxidant")	392	<u>L40</u>
<u>L39</u>	L38 and water	684	<u>L39</u>
<u>L38</u>	L36 and (PEG or "polyethyleneglycol" or "polyethylene glycol")	686	<u>L38</u>
<u>L37</u>	L36 and ("free-radical" near scaveng\$4)	2	<u>L37</u>
<u>L36</u>	L35 same (liquid or "fill material" or fill)	1054	<u>L36</u>
	(capsule or bolus or cap or dose or lozenge or pellet or pill or troche) same		
	("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium		
<u>L35</u>	metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium	6065	<u>L35</u>
	disulfite" or "disulfurous acid" or "disodium metabisulfite" or "sodium		
	pyrosulfite" or "sodium pyrosulphite" or metabisulfite or metabisulphite or		
	pyrosulfite or pyrosulphite)		
	(capsule or bolus or cap or dose or lozenge or pellet or pill or troche) and		
	("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium		
	metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium		

<u>L34</u>	disulfite" or "disulfurous acid" or "disodium metabisulfite" or "sodium pyrosulfite" or "sodium pyrosulphite" or metabisulfite or metabisulphite or pyrosulfite or pyrosulfite)	32315	<u>L34</u>
<u>L33</u>	L32 and (capsule same liquid)	609	<u>L33</u>
<u>L32</u>	L30 and @pd<20011004	987	<u>L32</u>
<u>L31</u>	L30 and (("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium disulfite" or "disulfurous acid" or "disodium metabisulfite" or "sodium pyrosulfite" or "sodium pyrosulphite" or metabisulfite or metabisulphite or pyrosulfite or pyrosulfite) near8 capsule)	7	<u>L31</u>
<u>L30</u>	L29 and capsule	6035	<u>L30</u>
<u>L29</u>	L27 and ("cross-linked" or denatur\$7 or (cross near3 link\$4))	14748	<u>L29</u>
<u>L28</u>	L27 and (capsule same ("cross-linked" or denatur\$7 or (cross near3 link\$4)))	0	<u>L28</u>
<u>L27</u>	("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium disulfite" or "disulfurous acid" or "disodium metabisulfite" or "sodium pyrosulfite" or "sodium pyrosulphite" or metabisulfite or metabisulphite or pyrosulfite or pyrosulfite)	70809	<u>L27</u>
<u>L26</u>	L24 and "cross-link"	18	<u>L26</u>
<u>L25</u>	L24 and ((sulfite or sulphite) near8 "cross-link\$4")	0	<u>L25</u>
<u>L24</u>	L23 and (pharmaceutical same capsule)	530	<u>L24</u>
<u>L23</u>	L21 and pharmaceutical	747	<u>L23</u>
<u>L22</u>	L21 and (("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium disulfite" or "disulfurous acid") near6 capsule)	34	<u>L22</u>
<u>L21</u>	L14 same capsule	914	<u>L21</u>
<u>L20</u>	L19 and (sulfite same capsule)	25	<u>L20</u>
<u>L19</u>	L17 and oral	1166	<u>L19</u>
<u>L18</u>	(L14 and L13) same capsule	3	<u>L18</u>
<u>L17</u>	L15 and capsule	1186	<u>L17</u>
<u>L16</u>	L14 same L13	13	<u>L16</u>
<u>L15</u>	L14 and L13	1301	<u>L15</u>
<u>L14</u>	("sodium metabisulfite" or "sodium bisulfite" or "sodium thiosulfate" or "sodium metabisulphite" or "sodium bisulphite" or "sodium pyrosulfite" or "sodium disulfite" or "disulfurous acid")	68023	<u>L14</u>
<u>L13</u>	(celecoxib or ("COX-2" near5 inhibitor\$3) or "4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzensulfonamide" or "SC 58635" or celebrex or "cyclooxygenase inhibitor")	9165	<u>L13</u>
	<i>DB=USPT; PLUR=YES; OP=OR</i>		
<u>L12</u>	(5733909 or 5874106 or 6214378 or 6214378).pn.	3	<u>L12</u>
	<i>DB=DWPI; PLUR=YES; OP=OR</i>		
<u>L11</u>	EP0695544.pn.	0	<u>L11</u>
	<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>		
<u>L10</u>	L9 and "cyclooxygenase-2"	14	<u>L10</u>

<u>L9</u>	L4 and capsule	41	<u>L9</u>
<u>L8</u>	L7 and capsule	1	<u>L8</u>
<u>L7</u>	David near4 Sperry	5	<u>L7</u>
<u>L6</u>	Gary near4 Ewing	13	<u>L6</u>
<u>L5</u>	Juliane near4 Bauer	4	<u>L5</u>
<u>L4</u>	Ping near Gao	57	<u>L4</u>
<i>DB=PGPB; PLUR=YES; OP=OR</i>			
<u>L3</u>	20040105884.pn.	1	<u>L3</u>
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<u>L2</u>	6231887.pn.	1	<u>L2</u>
<u>L1</u>	6579895.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

National Library of Medicine - Medical Subject Headings

2007 MeSH

MeSH Supplementary Concept Data

[Return to Entry Page](#)

Name of Substance	celecoxib
Record Type	C
Registry Number	169590-42-5
Entry Term	4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
Entry Term	Celebrex
Entry Term	Heumann brand of celecoxib
Entry Term	Mack brand of celecoxib
Entry Term	Parke Davis brand of celecoxib
Entry Term	Pfizer brand of celecoxib
Entry Term	Pharmacia Spain brand of celecoxib
Entry Term	Pharmacia brand of celecoxib
Entry Term	SC 58635
Entry Term	SC-58635
Entry Term	Searle brand of celecoxib
Heading Mapped to	*Pyrazoles
Heading Mapped to	*Sulfonamides
Indexing Information	Cardiovascular Diseases
Source	J Med Chem 1997 Apr 25;40(9):1347-65
Pharm. Action	Anti-Inflammatory Agents, Non-Steroidal
Pharm. Action	Cyclooxygenase Inhibitors
Frequency	1609
Note	inhibits COX-2 more than COX-1; structure in first source; cardiovascular risk found in long term cancer trial
Date of Entry	19970603
Revision Date	20041229
Unique ID	C105934

[Return to Entry Page](#)

[Link to NLM Cataloging Classification](#)

(FILE 'HOME' ENTERED AT 18:04:15 ON 15 FEB 2007)

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 18:04:28 ON 15 FEB 2007

L1 66564 S ((SODIUM (3A) (METABISULFITE OR BISULFITE OR THIOSULFATE OR M

FILE 'REGISTRY' ENTERED AT 18:23:25 ON 15 FEB 2007

L2 6 S CELECOXIB

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 18:23:50 ON 15 FEB 2007

L3 4601 S L2

L4 0 S L3 (P) L1

L5 102 S L3 AND L1

L6 77 S L5 AND (CAPSULE OR PILL OR TROCHE OR LOZENGE OR TROCHE)

L7 75 S L6 AND CAPSULE

L8 24 S L7 AND (CAPSULE (P) GELATIN?)

L9 20 DUPLICATE REMOVE L8 (4 DUPLICATES REMOVED)

L10 20 FOCUS L9 1-

FILE 'STNGUIDE' ENTERED AT 18:29:21 ON 15 FEB 2007

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 18:34:14 ON 15 FEB 2007

L11 13759 S ((CYCLOOXYGENASE(2A)2) (8A)INHIBIT?)

L12 4 S L11 (P) L1

L13 4 DUPLICATE REMOVE L12 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 18:36:55 ON 15 FEB 2007

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 18:38:52 ON 15 FEB 2007

L14 419 S L11 AND L1

L15 258 S L14 AND CAPSULE

L16 257 S L15 AND (WATER OR PEG OR (POLYETHYLENE(4A)GLYCOL))

L17 65 S L16 AND (ANTIOXIDANT OR (ANTI(3A)OXIDANT))

L18 23 S L17 AND (SURFACTANT OR POLYSORBATE OR (POLYSORBATE(4A)80))

L19 23 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> d que l1

L1 66564 SEA ((SODIUM (3A) (METABISULFITE OR BISULFITE OR THIOSULFATE
OR METABISULPHITE OR BISULPHITE OR PYROSULFITE OR DISULFITE))
OR (DISULFUROUS(W) ACID) OR (DISODIUM(W) METABISULFITE) OR
(SODIUM(3A) (PYROSULFITE OR PYROSULPHITE OR METABISULFITE OR
METABISULPHITE)))

L10 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

TI Pellicle-resistant gelatin capsule

AB The present invention relates to compns. suitable for use in preparing gelatin capsules for pharmaceutical, nutraceutical and food industries, to gelatin capsules exhibiting reduced crosslinking and/or pellicle formation, and to methods of preparing such gelatin capsules. Dosage forms comprising a drug, such as a cyclooxygenase-2 inhibitor are also described. For example, a composition suitable for preparation of a capsule wall contained gelatin 42%, glycerol (85%) 10%, sorbitol 15%, tromethamine 7.5%, and water 25.5%. Filled capsules were stored at 40° and 75% relative humidity for up to 24 wk. Capsules exhibit less pellicle formation than do capsules prepared from comparative composition with no primary amine.

ACCESSION NUMBER: 2004:550544 CAPLUS

DOCUMENT NUMBER: 141:94340

TITLE: Pellicle-resistant gelatin capsule

INVENTOR(S): Gao, Ping

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.--in-part of U.S. Pat. Appl. 2003 105,141.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004131670	A1	20040708	US 2003-633102	20030731
US 2003105141	A1	20030605	US 2002-119129	20020409
ZA 2003007575	A	20050103	ZA 2003-7575	20030929
PRIORITY APPLN. INFO.:			US 2001-284381P	P 20010417
			US 2001-326952P	P 20011004
			US 2002-119129	A2 20020409
			US 2002-399776P	P 20020731
			US 2002-399808P	P 20020731
			US 2002-399862P	P 20020731
			US 2002-399863P	P 20020731

OTHER SOURCE(S): MARPAT 141:94340

L10 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

TI Pellicle-resistant gelatin capsule

AB The present invention relates to compns. suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced crosslinking, and to methods of preparing such gelatin capsules. The compns. comprise gelatin and an amine agent used for inhibition of crosslinking of the gelatin and/or pellicle formation in a capsule shell. The amine agent is selected from tromethamines, ethanolamine, ethylenediamine, diethylamine, ethylene N-methyl-D-glucamine, amino acids, diethanolamine, benethamine, benzathine, piperazine, hydrabamine, and imidazoles. The compns. further comprise at list one excipient selected from decomposition inhibitors, opacifying agents, preservatives, and plasticizers. Capsules are useful for oral delivery of drugs, e.g., a selective cyclooxygenase-2 inhibitory drugs, such as celecoxib. For example, a capsule wall was prepared from gelatin 40%, 85% glycerol 25%, tromethamine 10%, and water 25%. The capsules were filled and after 24 wk storage at 40° and 75% relative humidity exhibited less pellicle formation than did capsules prepared from comparative composition with no primary amine.

ACCESSION NUMBER: 2004:100974 CAPLUS

DOCUMENT NUMBER: 140:151970

TITLE: Pellicle-resistant gelatin capsule

INVENTOR(S): Gao, Ping
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010972	A2	20040205	WO 2003-US24042	20030731
WO 2004010972	A3	20040729		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2494069	A1	20040205	CA 2003-2494069	20030731
AU 2003257981	A1	20040216	AU 2003-257981	20030731
EP 1526844	A2	20050504	EP 2003-772159	20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012875	A	20050628	BR 2003-12875	20030731
JP 2005538993	T	20051222	JP 2004-524261	20030731
PRIORITY APPLN. INFO.:				
			US 2002-399776P	P 20020731
			US 2002-399808P	P 20020731
			US 2002-399862P	P 20020731
			US 2002-399863P	P 20020731
			WO 2003-US24042	W 20030731

OTHER SOURCE(S): MARPAT 140:151970

L10 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Gelatin capsule exhibiting reduced cross-linking
 AB The present invention relates to compns. suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced crosslinking, and to methods of preparing such gelatin capsules. The compns. comprise gelatin and a sulfite compound used for inhibition of gelatin crosslinking and/or pellicle formation in a capsule shell. The composition further comprises at least one excipient selected from decomposition inhibitors, opacifying agents, preservatives, and plasticizers. Capsules are useful for oral delivery of drugs, e.g., a selective cyclooxygenase-2 inhibitory drugs, such as celecoxib. For example, a capsule wall was prepared from gelatin 42%, 85% glycerol 10%, sorbitol 15%, sodium bisulfite 7.5%, and water 25.5%. The capsules were filled and after a 24 wk storage at 40° and 75% relative humidity exhibited less pellicle formation than did capsules prepared from comparative composition with no bisulfite.

ACCESSION NUMBER: 2004:100976 CAPLUS
 DOCUMENT NUMBER: 140:151972
 TITLE: Gelatin capsule exhibiting reduced cross-linking
 INVENTOR(S): Gao, Ping
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010974	A2	20040205	WO 2003-US24045	20030731
WO 2004010974	A3	20040805		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2493980	A1	20040205	CA 2003-2493980	20030731
AU 2003257103	A1	20040216	AU 2003-257103	20030731
EP 1526846	A2	20050504	EP 2003-772161	20030731
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003013150	A	20050628	BR 2003-13150	20030731
JP 2005538102	T	20051215	JP 2004-524263	20030731
PRIORITY APPLN. INFO.:			US 2002-399776P	P 20020731
			US 2002-399808P	P 20020731
			US 2002-399862P	P 20020731
			US 2002-399863P	P 20020731
			WO 2003-US24045	W 20030731

OTHER SOURCE(S): MARPAT 140:151972

L10 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

TI Gelatin capsule exhibiting reduced crosslinking with addition of sulfites

AB The present invention relates to compns. suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced crosslinking, and to methods of preparing such gelatin capsules. Capsules prepared from compns. containing a sulfite such as Na bisulfite or Na metabisulfite exhibit less pellicle formation than do capsules prepared without the sulfites.

ACCESSION NUMBER: 2004:451483 CAPLUS

DOCUMENT NUMBER: 140:429045

TITLE: Gelatin capsule exhibiting reduced crosslinking with addition of sulfites

INVENTOR(S): Gao, Ping

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 119,129.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 9

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004105885	A1	20040603	US 2003-633194	20030731
US 2003105141	A1	20030605	US 2002-119129	20020409
ZA 2003007575	A	20050103	ZA 2003-7575	20030929
PRIORITY APPLN. INFO.:			US 2001-284381P	P 20010417
			US 2001-326952P	P 20011004
			US 2002-119129	A2 20020409
			US 2002-399776P	P 20020731
			US 2002-399808P	P 20020731
			US 2002-399862P	P 20020731

OTHER SOURCE(S): MARPAT 140:429045

L10 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical dosage form comprising a sulfite compound
AB The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility and (b) a sulfite compound in an amount sufficient to inhibit crosslinking of gelatin in the gelatin capsule upon storage of the dosage form in a closed container maintained at 40° and 75% relative humidity for a period of 6 mo. For example, a soft capsule was formulated containing celecoxib 270, PEG-400 335, Tween 80 195, oleic acid 78, HPMC 74, DMAE 35, Pr gallate 2, water 7, and Na metabisulfite 4 parts.

ACCESSION NUMBER: 2004:451482 CAPLUS
DOCUMENT NUMBER: 141:12299
TITLE: Pharmaceutical dosage form comprising a sulfite compound
INVENTOR(S): Gao, Ping; Bauer, Juliane M.; Ewing, Gary D.; Sperry, David C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 119,129.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004105884	A1	20040603	US 2003-632737	20030731
US 2003105141	A1	20030605	US 2002-119129	20020409
ZA 2003007575	A	20050103	ZA 2003-7575	20030929
PRIORITY APPLN. INFO.:			US 2001-284381P	P 20010417
			US 2001-326952P	P 20011004
			US 2002-119129	A2 20020409
			US 2002-399776P	P 20020731
			US 2002-399808P	P 20020731
			US 2002-399862P	P 20020731
			US 2002-399863P	P 20020731

OTHER SOURCE(S): MARPAT 141:12299

L10 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
AB The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule, wherein the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility and (b) a primary or secondary amine compound in an amount sufficient to inhibit crosslinking of gelatin in the gelatin capsule upon storage of the dosage form in a closed container maintained at 40° and 75% relative humidity for a period of 6 mo. For example, a composition containing celecoxib 200, PEG-400 271, Tween-80 217, oleic acid 61, PVP 47, ethanol 113, hydroxypropyl Me cellulose 39, water 26, Pr gallate 1, tromethamine 26 parts were filled into soft gelatin capsules. The capsules exhibited no pellicle formation during storage for a period of 6 mo at 40° and 75% relative humidity.

ACCESSION NUMBER: 2004:451481 CAPLUS
DOCUMENT NUMBER: 141:12298
TITLE: Pharmaceutical dosage form capable of maintaining

stable dissolution profile upon storage
 INVENTOR(S): Gao, Ping; Bauer, Juliane M.; He, Xiaorong
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. Ser. No. 119,129.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004105883	A1	20040603	US 2003-633390	20030731
US 2003105141	A1	20030605	US 2002-119129	20020409
ZA 2003007575	A	20050103	ZA 2003-7575	20030929
PRIORITY APPLN. INFO.:			US 2001-284381P	P 20010417
			US 2001-326952P	P 20011004
			US 2002-119129	A2 20020409
			US 2002-399776P	P 20020731
			US 2002-399808P	P 20020731
			US 2002-399862P	P 20020731
			US 2002-399863P	P 20020731

OTHER SOURCE(S): MARPAT 141:12298

L10 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Gelatin capsules capable of maintaining stable dissolution profile of COX-2 inhibitors upon storage
 AB The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a primary or secondary amine compound in an amount sufficient to inhibit crosslinking of gelatin in the capsule upon storage of the dosage form in a closed container maintained at 40° and 75% relative humidity for a period of 6 mo. For example, soft gelatin capsules filled with a formulation containing celecoxib 200 mg, PEG 400 271 mg, Tween 80 217 mg, oleic acid 61 mg, PVP 47 mg, ethanol 113 mg, hydroxypropyl Me cellulose 38 mg, water 25 mg, Pr gallate 1 mg, and tromethamine 26 mg (.apprx. 3%), after a 24 wk storage at 40° and 75% relative humidity, exhibited no pellicle formation. By contrast, capsules containing no amine or 0.5% tromethamine exhibited pellicle formation by 2 and 4 wk of storage, resp.

ACCESSION NUMBER: 2004:100975 CAPLUS
 DOCUMENT NUMBER: 140:151971
 TITLE: Gelatin capsules capable of maintaining stable dissolution profile of COX-2 inhibitors upon storage
 INVENTOR(S): Gao, Ping; Bauer, Juliane M.; He, Xiaorong
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010973	A2	20040205	WO 2003-US24043	20030731
WO 2004010973	A3	20040805		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,			

PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2494358 A1 20040205 CA 2003-2494358 20030731
 AU 2003257982 A1 20040216 AU 2003-257982 20030731
 EP 1526845 A2 20050504 EP 2003-772160 20030731
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003013149 A 20050628 BR 2003-13149 20030731
 JP 2005538994 T 20051222 JP 2004-524262 20030731
 PRIORITY APPLN. INFO.: US 2002-399776P P 20020731
 US 2002-399808P P 20020731
 US 2002-399862P P 20020731
 US 2002-399863P P 20020731
 WO 2003-US24043 W 20030731

OTHER SOURCE(S): MARPAT 140:151971

L10 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Pharmaceutical dosage form comprising a sulfite compound
 AB The present invention provides a pharmaceutical dosage form comprising a
 fill material sealed in a gelatin capsule; the fill
 material comprises (a) a selective COX-2 inhibitory drug of low water
 solubility, and (b) a sulfite compound in an amount sufficient to inhibit
 crosslinking of gelatin in said gelatin
 capsule upon storage of the dosage form in a closed container
 maintained at 40°C and 75% relative humidity for a period of 6 mo.
 Capsules containing celecoxib 278, Tween-80 195, PEG-400 337, oleic acid 80,
 hydroxypropyl Me cellulose 74, Pr gallate 2, dimethylamino-ethanol 34
 35Total 34. Celecoxib capsules containing sodium
 metabisulfite in an amount of about 3% by weight of the fill material
 exhibited no pellicle formation during storage for a period of six months,
 as compared with capsules containing no sulfite compound which exhibited
 pellicle formation by two weeks of storage.

ACCESSION NUMBER: 2004:220182 CAPLUS
 DOCUMENT NUMBER: 140:259114
 TITLE: Pharmaceutical dosage form comprising a sulfite
 compound
 INVENTOR(S): Gao, Ping; Bauer, Juliane M.; Ewing, Gary; Sperry,
 David
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 9
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022032	A2	20040318	WO 2003-US24044	20030731
WO 2004022032	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

CA 2493974	A1	20040318	CA 2003-2493974	20030731
AU 2003257102	A1	20040329	AU 2003-257102	20030731
EP 1526847	A2	20050504	EP 2003-794452	20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013064	A	20050628	BR 2003-13064	20030731
JP 2006500389	T	20060105	JP 2004-534259	20030731
PRIORITY APPLN. INFO.:			US 2002-399776P	P 20020731
			US 2002-399808P	P 20020731
			US 2002-399862P	P 20020731
			US 2002-399863P	P 20020731
			WO 2003-US24044	W 20030731
OTHER SOURCE(S):		MARPAT 140:259114		

L13 ANSWER 2 OF 4 USPATFULL on STN
AN 2004:138712 USPATFULL
TI Pharmaceutical dosage form comprising a sulfite compound
IN Gao, Ping, Portage, MI, UNITED STATES
Bauer, Julianne M., Portage, MI, UNITED STATES
Ewing, Gary D., Kalamazoo, MI, UNITED STATES
Sperry, David C., Kalamazoo, MI, UNITED STATES
PI US 2004105884 A1 20040603
AI US 2003-632737 A1 20030731 (10)
RLI Continuation-in-part of Ser. No. US 2002-119129, filed on 9 Apr 2002,
PENDING
PRAI US 2001-284381P 20010417 (60)
US 2001-326952P 20011004 (60)
US 2002-399862P 20020731 (60)
US 2002-399776P 20020731 (60)
US 2002-399863P 20020731 (60)
US 2002-399808P 20020731 (60)
DT Utility
FS APPLICATION
LN.CNT 1150
INCL INCLM: 424/456.000
INCLS: 424/703.000; 514/406.000; 514/473.000; 514/458.000; 514/474.000
NCL NCLM: 424/456.000
NCLS: 424/703.000; 514/406.000; 514/458.000; 514/473.000; 514/474.000
IC [7]
ICM A61K031-415
ICS A61K009-64; A61K031-355; A61K033-04
IPCI A61K0031-415 [ICM,7]; A61K0009-64 [ICS,7]; A61K0009-52
[ICS,7,C*]; A61K0031-355 [ICS,7]; A61K0031-352 [ICS,7,C*];
A61K0033-04 [ICS,7]
IPCR A61K0009-107 [I,C*]; A61K0009-107 [I,A]; A61K0009-48 [I,C*];
A61K0009-48 [I,A]; A61K0009-52 [I,C*]; A61K0009-64 [I,A];
A61K0031-00 [I,C*]; A61K0031-00 [I,A]; A61K0031-18 [I,C*];
A61K0031-18 [I,A]; A61K0031-415 [I,C*]; A61K0031-415 [I,A];
A61K0031-63 [I,C*]; A61K0031-635 [I,A]
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 3 OF 4 USPATFULL on STN
AN 2003:214435 USPATFULL
TI Fluoro-substituted benzenesulfonyl compounds for the treatment of
inflammation
IN Brown, David L., Chesterfield, MO, UNITED STATES
Graneto, Matthew J., Chesterfield, MO, UNITED STATES
Ludwig, Cindy L., St. Louis, MO, UNITED STATES
Molyneaux, John M., St. Louis, MO, UNITED STATES
Talley, John J., Cambridge, MA, UNITED STATES
PA Pharmacia Corporation (U.S. corporation)
PI US 2003149078 A1 20030807
US 6699884 B2 20040302
AI US 2002-319916 A1 20021213 (10)
RLI Continuation of Ser. No. US 2002-124209, filed on 16 Apr 2002, PENDING
PRAI US 2001-285264P 20010420 (60)
DT Utility
FS APPLICATION
LN.CNT 11198
INCL INCLM: 514/336.000
INCLS: 514/340.000; 514/341.000; 514/374.000; 514/406.000; 514/365.000;
514/397.000; 514/394.000; 514/604.000; 546/269.700; 546/271.400;
546/272.700; 546/275.400; 546/283.400; 546/272.100; 548/202.000;
548/215.000; 548/240.000; 548/304.400; 548/354.100; 548/377.100
NCL NCLM: 514/336.000
NCLS: 514/357.000; 514/408.000; 514/520.000; 514/602.000; 514/709.000;
546/268.100; 546/329.000; 546/330.000; 546/339.000; 548/413.000;

548/577.000; 564/084.000; 564/085.000; 564/086.000; 568/028.000;
 568/029.000; 514/340.000; 514/341.000; 514/365.000; 514/374.000;
 514/394.000; 514/397.000; 514/406.000; 514/604.000; 546/269.700;
 546/271.400; 546/272.100; 546/272.700; 546/275.400; 546/283.400;
 548/202.000; 548/215.000; 548/240.000; 548/304.400; 548/354.100;
 548/377.100

IC [7]
 ICM A61K031-4439
 ICS A61K031-4433; A61K031-427; A61K031-422; A61K031-4184;
 A61K031-4178
 IPCI A61K0031-4439 [ICM,7]; A61K0031-4433 [ICS,7]; A61K0031-4427
 [ICS,7,C*]; A61K0031-427 [ICS,7]; A61K0031-422 [ICS,7];
 A61K0031-4184 [ICS,7]; A61K0031-4178 [ICS,7]; A61K0031-4164
 [ICS,7,C*]
 IPCI-2 A61K0031-40 [ICM,7]; A61K0031-44 [ICS,7]; C07C0317-32 [ICS,7];
 C07C0317-00 [ICS,7,C*]; C07D0213-02 [ICS,7]; C07D0213-00
 [ICS,7,C*]
 IPCR C07D0231-00 [I,C*]; C07D0231-12 [I,A]; C07D0261-00 [I,C*];
 C07D0261-08 [I,A]; C07D0307-00 [I,C*]; C07D0307-32 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 4 OF 4 USPATFULL on STN

AN 2003:45345 USPATFULL

TI Fluoro-substituted benzenesulfonyl compounds for the treatment of
 inflammation

IN Brown, David L., Chesterfield, MO, UNITED STATES
 Graneto, Matthew J., Chesterfield, MO, UNITED STATES
 Ludwig, Cindy L., St. Louis, MO, UNITED STATES
 Molyneaux, John M., St. Louis, MO, UNITED STATES
 Talley, John J., St. Louis, MO, UNITED STATES

PA Pharmacia Corporation (U.S. corporation)

PI US 2003032657 A1 20030213

US 6673818 B2 20040106

AI US 2002-124209 A1 20020416 (10)

PRAI US 2001-285264P 20010420 (60)

DT Utility

FS APPLICATION

LN.CNT 11199

INCL INCLM: 514/336.000

INCLS: 514/357.000; 514/408.000; 514/520.000; 514/602.000; 514/709.000;
 546/268.100; 546/339.000; 546/329.000; 546/330.000; 548/577.000;
 558/413.000; 564/084.000; 564/085.000; 564/086.000; 568/028.000;
 568/029.000

NCL NCLM: 514/332.000; 514/336.000

NCLS: 514/277.000; 514/340.000; 514/341.000; 514/357.000; 514/378.000;
 514/406.000; 514/438.000; 514/473.000; 514/604.000; 514/703.000;
 546/255.000; 546/272.100; 546/272.700; 546/334.000; 546/339.000;
 548/247.000; 548/375.100; 548/376.100; 549/059.000; 549/321.000;
 549/323.000; 564/090.000; 568/028.000; 514/408.000; 514/520.000;
 514/602.000; 514/709.000; 546/268.100; 546/329.000; 546/330.000;
 548/577.000; 558/413.000; 564/084.000; 564/085.000; 564/086.000;
 568/029.000

IC [7]

ICM A61K031-4439

ICS A61K031-44; A61K031-40; A61K031-277; C07C317-32

IPCI A61K0031-4439 [ICM,7]; A61K0031-4427 [ICM,7,C*]; A61K0031-44
 [ICS,7]; A61K0031-40 [ICS,7]; A61K0031-277 [ICS,7]; A61K0031-275
 [ICS,7,C*]; C07C0317-32 [ICS,7]; C07C0317-00 [ICS,7,C*]

IPCI-2 C07D0401-02 [ICM,7]; C07D0401-00 [ICM,7,C*]; A61K0031-44 [ICS,7]

IPCR C07D0231-00 [I,C*]; C07D0231-12 [I,A]; C07D0261-00 [I,C*];

C07D0261-08 [I,A]; C07D0307-00 [I,C*]; C07D0307-32 [I,A]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 9 OF 23 USPATFULL on STN

TI Stabilized oral pharmaceutical composition

AB An orally deliverable pharmaceutical composition is provided comprising an aminosulfonyl-comprising drug, for example a selective cyclooxygenase-2 inhibitory drug such as celecoxib, and a solvent liquid comprising a polyethylene glycol and one or more free radical-scavenging antioxidants. At least a substantial part of the drug is in dissolved form in the solvent liquid. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders.

ACCESSION NUMBER: 2005:130738 USPATFULL

TITLE: Stabilized oral pharmaceutical composition

INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES
Huang, Tiehua, Kalamazoo, MI, UNITED STATES
Robins, Russell H., Portage, MI, UNITED STATES
Bauer, Julianne M., Portage, MI, UNITED STATES
Guido, Jane E., Vicksburg, MI, UNITED STATES
Brugger, Andrew M., Libertyville, IL, UNITED STATES
Karim, Aziz, Skokie, IL, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005112197	A1	20050526
APPLICATION INFO.:	US 2004-969140	A1	20041020 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-119118, filed on 9 Apr 2002, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284589P	20010417 (60)
	US 2002-357959P	20020219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST OFFICE BOX 1027, ST. LOUIS, MO, 63006, US	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2122	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 15 OF 23 USPATFULL on STN

TI Gelatin capsule exhibiting reduced cross-linking

AB The present invention relates to compositions suitable for use in preparing gelatin capsules, to gelatin capsules exhibiting reduced cross-linking, and to methods of preparing such gelatin capsules.

ACCESSION NUMBER: 2004:138713 USPATFULL

TITLE: Gelatin capsule exhibiting reduced cross-linking

INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004105885	A1	20040603
APPLICATION INFO.:	US 2003-633194	A1	20030731 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-119129, filed on 9 Apr 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284381P	20010417 (60)
	US 2001-326952P	20011004 (60)

US 2002-399862P 20020731 (60)
US 2002-399776P 20020731 (60)
US 2002-399863P 20020731 (60)
US 2002-399808P 20020731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST
OFFICE BOX 1027, ST. LOUIS, MO, 63006
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1197
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 17 OF 23 USPATFULL on STN

TI Pharmaceutical dosage form capable of maintaining stable dissolution
profile upon storage

AB The present invention provides a pharmaceutical dosage form comprising a
fill material sealed in a gelatin capsule; the fill material
comprises (a) a selective COX-2 inhibitory drug of low water
solubility, and (b) a primary or secondary amine compound in an amount
sufficient to inhibit cross-linking of gelatin in said gelatin
capsule upon storage of the dosage form in a closed container
maintained at 40° C. and 75% relative humidity for a period of 6
months.

ACCESSION NUMBER: 2004:138711 USPATFULL
TITLE: Pharmaceutical dosage form capable of maintaining
stable dissolution profile upon storage
INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES
Bauer, Juliane M., Portage, MI, UNITED STATES
He, Xiaorong, Kalamazoo, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004105883	A1	20040603
APPLICATION INFO.:	US 2003-633390	A1	20030731 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-119129, filed on 9 Apr 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284381P	20010417 (60)
	US 2001-326952P	20011004 (60)
	US 2002-399862P	20020731 (60)
	US 2002-399776P	20020731 (60)
	US 2002-399863P	20020731 (60)
	US 2002-399808P	20020731 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PHARMACIA CORPORATION, GLOBAL PATENT DEPARTMENT, POST
OFFICE BOX.1027, ST. LOUIS, MO, 63006
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 1165
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 20 OF 23 USPATFULL on STN

TI Stabilized oral pharmaceutical composition

AB An orally deliverable pharmaceutical composition is provided comprising
an aminosulfonyl-comprising drug, for example a selective
cyclooxygenase-2 inhibitory drug such as
celecoxib, and a solvent liquid comprising a polyethylene
glycol and one or more free radical-scavenging antioxidants. At

least a substantial part of the drug is in dissolved form in the solvent liquid. The composition has rapid-onset properties and is useful in treatment of cyclooxygenase-2 mediated conditions and disorders.

ACCESSION NUMBER: 2003:153476 USPATFULL
TITLE: Stabilized oral pharmaceutical composition
INVENTOR(S): Gao, Ping, Portage, MI, UNITED STATES
Huang, Tiehua, Kalamazoo, MI, UNITED STATES
Robins, Russell H., Portage, MI, UNITED STATES
Bauer, Juliane M., Portage, MI, UNITED STATES
Guido, Jane E., Vicksburg, MI, UNITED STATES
Brugger, Andrew M., Libertyville, IL, UNITED STATES
Karim, Aziz, Skokie, IL, UNITED STATES
Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Glenview, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003105144	A1	20030605
APPLICATION INFO.:	US 2002-119118	A1	20020409 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-284589P	20010417 (60)
	US 2002-357959P	20020219 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Pharmacia Corporation, Patent Department, 800 N. Lindbergh Boulevard-04E, St. Louis, MO, 63167	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2152	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 23 OF 23 USPATFULL on STN

TI Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
AB A therapeutic combination useful in the treatment, amelioration, prevention, or delay of pain comprising a high energy form of a selective cyclooxygenase-2 inhibitor, a vasomodulator, and a pharmaceutically acceptable excipient, carrier, or diluent, the cyclooxygenase-2 inhibitor and vasomodulator each being present in an amount effective to contribute to the treatment, prevention, amelioration or delay of pain.

ACCESSION NUMBER: 2002:149172 USPATFULL
TITLE: Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
INVENTOR(S): Hassan, Fred, Peapack, NJ, UNITED STATES
Forbes, James C., Skokie, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002077328	A1	20020620
APPLICATION INFO.:	US 2001-905292	A1	20010713 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296196P	20010606 (60)
	US 2001-284248P	20010417 (60)
	US 2000-218101P	20000713 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SENNIGER POWERS LEAVITT AND ROEDEL, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102	

NUMBER OF CLAIMS: 125
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 4527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.